Vaccine

In vivo assays play a crucial role in the assessment of the potency and safety of human vaccines. Efficient translation from basic research to clinical therapies will depend on the availability of appropriate vaccine animal model to address every problem that arises during vaccine development.

Toxoid vaccines refer to two vaccines contain toxoids as the immunogen, the vaccines against diphtheria and tetanus. A toxoid is an inactivated toxin that has lost its ability to cause disease but has retained its immunogenicity. (The pertussis vaccine also contains toxoid but contains other bacterial proteins as well.)

Nanotechnology is increasingly important in vaccine development. As vaccines are evolving toward less immunogenic minimalist compositions, adjuvants and delivery systems that increase the effectiveness of the antigen are of increasing importance. The use of nanoparticles in vaccine formulations not only improves antigen immunogenicity and stability, more importantly, targeted nanoparticle vaccine delivery and controlled release are also achieved.

The mechanisms of adjuvants mainly include broadening vaccine protection by extending the presence of antigen in the blood, improving immune response by helping absorb the antigen presenting cells antigen, supporting the production of cytokines, activating lymphocytes and macrophages.

Most of the time when the cancer is diagnosed, it is already well established and has largely evaded the control of the immune system. In this context, therapeutic cancer vaccine has been developed to stimulate or boost the immune system of the patient against established tumors.

The first HBV vaccine development was finished in the United States in 1981 and the recombinant version appeared on the market in 1986. It is the most effective and safe drugs required for health systems, which is in the list of essential medicines of the World Health Organization.

GLP vaccine safety refers that Vaccine development requires pre-clinical toxicology studies, following good laboratory practice (GLP), before first in human (phase I) use.

Vaccines exist in many different forms which may contain live, attenuated virus, or an inactivated micro-organism, or some unique molecular component of the organism that causes illnesses. Vaccines can generally be classified as Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Vector Vaccine, Conjugate Vaccine, DNA and RNA Vaccine and more.

Vaccines have long been used to fight against infectious diseases and most currently available vaccines were empirically designed. However, immune evasion by pathogens often lead to difficulty in vaccine development. Revolutionary changes happened in the approach to vaccine design and development in the last decade.

Vaccine test play a crucial role in the assessment of the potency and safety of human vaccines. Efficient translation from basic research to clinical therapies will depend on the availability of appropriate animal models to address every problem that arises during vaccine development.

Well vaccine customized development of a vaccine project requires an experienced partner who understands the unique complexity presented by this important research area. Close cooperation between professional laboratories and clinical research teams is essential for ensuring good sample handling, tracking and data reporting, and successful completion of vaccine research.

Vaccines can generally be classified as Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Vector Vaccine, Conjugate Vaccine, DNA and RNA Vaccine and more.

Currently, in a new era of cancer immunotherapy, vaccines are being considered as a new treatment. Over these years, cancer vaccine field has been stagnant due to the lack of exciting breakthrough until the great success and rapid development of immunotherapy. Now cancer vaccine research has aroused the public's attention. According to a survey by the Cancer Research Institute (CRI), there are more than 300 cancer vaccine candidates in clinical trials across the industry. At the same time, advances in gene sequencing and machine learning in recent years have made it possible to tailor the vaccine to each patient technically. Despite these advances, there still remain some obstacles.

Cancer vaccines can be used to train the immune system to recognize antigens. An antigen is a protein tag presented by a cell that can elicit an immune response. By studying antigens that are overexpressed by tumor cells, in theory, researchers can trigger the body's defense system to identify cancer as an invader. In practice, the selection of a suitable antigen (or combination of antigens) to activate T cells has proven to be difficult, as is the finding of a suitable vaccine delivery vector. BioNTech's Marett explained that there was no computing power 10 years ago to effectively use algorithms to select mutations suitable for developing vaccines from the vast array of next-generation sequencing (NGS sequencing)data. Currently, some companies are exploring whether mining new antigens may be a better way to build cancer vaccines, including BioNTech, Neon Therapeutics, Gritstone Oncology, and Moderna.

Nucleic acid vaccines, genetic vaccines or DNA vaccine, are also known as naked nucleic acid vaccines because they do not require carriers and adjuvants for intramuscular injection. This vaccine, through intramuscular injection, provides longer-lasting antigen expression in muscle cells that induces antibody production, T cell proliferation, and cytokine release, particularly inducing cytotoxic T cells (CTL). At present, there are about 30 kinds of HIV vaccines including recombinant genetic engineering vaccines, nucleic acid vaccines and live attenuated vaccine in various clinical trials around the world. The SARS virus inactivated vaccine research has achieved some results. Many infectious diseases are still vaccinated or are still in preclinical research.

What is a vaccine? The vaccine is an autoimmune preparation for preventing infectious diseases by artificially attenuating, inactivating or using genetic engineering methods for pathogenic microorganisms (such as bacteria, rickettsia, inactivated virus, etc.) and their metabolites. The vaccine retains the characteristics of the pathogen to stimulate the immune system of the animal. When the human body comes into contact with such non-invasive pathogens, the immune system will produce certain protective substances, such as immune hormones, active physiological substances, special antibodies, etc.; when the human body comes into contact with the pathogen again, the body's immune system will follow the original memory and create more protective substances to prevent the damage of pathogens.